Library TCR T cell therapy - Alaunos Therapeutics
Latest Information Update: 15 Dec 2023
At a glance
- Originator Alaunos Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Lung cancer; Ovarian cancer
Most Recent Events
- 20 Nov 2023 Discontinued - Phase-I/II for Endometrial cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) before August 2023
- 20 Nov 2023 Discontinued - Phase-I/II for Lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) before August 2023
- 20 Nov 2023 Discontinued - Phase-I/II for Ovarian cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) before August 2023